Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Syndromic Multiplex Diagnostic Market - Growth, Trends, and Forecasts (2020 - 2025)

Published by Mordor Intelligence Pvt Ltd Product code 921984
Published Content info 115 Pages
Delivery time: 2-3 business days
Back to Top
Syndromic Multiplex Diagnostic Market - Growth, Trends, and Forecasts (2020 - 2025)
Published: August 1, 2020 Content info: 115 Pages

The syndromic multiplex diagnostic market is anticipated to grow with a CAGR of nearly 7.2% during the forecast period. The major factors attributing to the growth of the syndromic multiplex diagnostic market include rise in the number of infectious cases and diseases and higher incidence of side effects associated with the use of antibiotics which demand proper diagnostics.

Thus, owing to its ability to address the rising needs of the patients and clinicians like utilization of lesser resources, enhanced accuracy of results are believed to lead the syndromic multiplex diagnostic market to grow throughout the forecast period. For instance, in May 2018, according to the World Health Organization, the leading cause of deaths recorded worldwide were lower respiratory infections necessitating the high requirement for advanced diagnostic equipment which fuel the global syndromic multiplex diagnostic market.

Key Market Trends

Respiratory Syndrome is Expected to Hold the Major Market Share in the Syndromic Multiplex Diagnostic Market

Respiratory syndromes account for the largest share of the syndromic multiplex diagnostics market and expected to continue the same throughout the forecast period. This dominance mainly due to factors such as the higher demand due to the rapid spread of infections along with the launch of new products with USFDA approvals in the segment that contributes to its major revenue share in the global market.

By End-user, hospitals account for the largest share due to the availability of all resources at a single facility. Also, the reduction of the overall stay of patients for treatment in hospitals with the reduced procedural time along with minimal or no uncertainties, and errors in the treatments is expected to fuel the market during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America has been the primary market for the syndromic multiplex diagnostic market and is expected to hold a significant share in global revenue owing to the adoption of advanced technologies and the availability of improved healthcare infrastructure, and also rise in R&D laboratories resultant.

Globally, the syndromic multiplex diagnostics market is expected to witness the fastest growth in Asia-Pacific region during the forecast period due to the higher demand for treatments with widespread infections, rise in government support to spread the healthcare awareness among people about various infections in the region.

Competitive Landscape

The Global Syndromic multiplex diagnostic market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are launching new products, while others are distributing the products, making acquisitions and partnerships to increase their footprints in the market. Some of the companies which are currently dominating the market are BIOMERIEUX SA, Luminex Corporation, QIAGEN, Applied BioCode, and Akonni Biosystems.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Table of Contents
Product Code: 67634



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Accurate and Rapid Results
    • 4.2.2 Quick Access to the Treatment and Reduction of the Adverse Reactions of Antibiotics
  • 4.3 Market Restraints
    • 4.3.1 Reluctance by Doctors and lack of Skilled Professional
    • 4.3.2 Inability in Detecting Asymptomatic Cases
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Type of Syndrome
    • 5.1.1 Respiratory
    • 5.1.2 Gastrointestinal
    • 5.1.3 Central Nervous System
    • 5.1.4 Others
  • 5.2 By End-user
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostics Laboratories
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 BIOMERIEUX SA
    • 6.1.2 Qiagen
    • 6.1.3 Luminex Corporation
    • 6.1.4 Applied BioCode
    • 6.1.5 Akonni Biosystems
    • 6.1.6 Mesa Biotech
    • 6.1.7 Abbott Laboratories
    • 6.1.8 Accelerate Diagnostic
    • 6.1.9 Diagenode Diagnostics
    • 6.1.10 Hologic, Inc.


Back to Top